Clinical Trial Update: A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing cobimetinib plus atezolizumab versus pembrolizumab in previously untreated advanced BRAFV600 wild-type melanoma; study terminated with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brafv600 Wild-type Melanoma
• Melanoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Cobimetinib (cobimetinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Advanced BRAFV600 Wild-type Melanoma | Phase 3 | Status: TERMINATED | Results posted: 2020-06-09